Does gender parity exist in Fabry disease?

Neurology

Volumn 65, Issue 4, 2005, Pages 508-509

  Percy, Alan K ^a,d   Kaye, Edward M ^b,c  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b GENZYME CORPORATION   (United States)

^c BOSTON CHILDREN S HOSPITAL   (United States)

^d CIRC 329A ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GENE PRODUCT; GLYCOSPHINGOLIPID; HYDROLASE;

BRAIN BLOOD FLOW; CEREBROVASCULAR DISEASE; EDITORIAL; ENZYME ACTIVITY; ENZYME REPLACEMENT; FABRY DISEASE; GENDER; GENE; HETEROZYGOTE; HUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RISK; STROKE; TRANSIENT ISCHEMIC ATTACK; WHITE MATTER; X CHROMOSOME; X CHROMOSOME INACTIVATION;

EID: 23844496419     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.wnl.0000176869.88481.8d     Document Type: Editorial

References (10)

1. Ross MT, Grafham DV, Coffey AJ et al. The DNA sequence of the human X chromosome. Nature 2005;434:325-337.
2. Carrel L, Willard HF. X-inactivation profile reveals extensive variability in X-linked gene expression in females. Nature 2005; 434: 400-404.
3. Crutchfield KE, Patronas NJ, Dambrosia JM et al. Quantitative analysis of cerebral vasculopathy in patients with Fabry disease. Neurology 1998;50:1746-1749.
4. MacDermot KD, Holmes A, Miners AH. Natural history of Fabry disease in affected males and obligate carrier females. J Inherit Metab Dis 2001;24(suppl 2):13-14.
5. Whybra C, Kampmann C, Willers I et al. Anderson-Fabry disease: clinical manifestations of disease in female heterozygotes. J Inherit Metab Dis 2001;24:715-724.
6. Fellgiebel A, Müller MJ, Mazanek M, Baron K, Beck M, Stoeter P. White matter lesion severity in male and female patients with Fabry disease. Neurology 2005;65:600-602.
7. Altarescu G, Moore DF, Schiffmann R. Effect of genetic modifiers on cerebral lesions in Fabry disease. Neurology 2005;64:2148-2150.
8. Moore DF, Scott LT, Gladwin MT et al. Regional cerebral hyperperfusion and nitric oxide pathway dysregulation in Fabry disease: reversal by enzyme replacement therapy. Circulation 2001;104:1506-1512.
9. Hilz MJ, Kolodny EH, Brys M et al. Reduced cerebral blood flow velocity and impaired cerebral autoregulation in patients with Fabry disease. J Neurol 2004;251:564-570.
10. Moore DP, Altarescu G, Ling GS et al. Elevated cerebral blood flow velocities in Fabry disease with reversal after enzyme replacement. Stroke 2002;33:525-531.